CD274 and esophageal squamous cell carcinoma: Some limitations of this NMA must be acknowledged: although the group with high PD-L1 expression in ESCC benefited more from PD-1 plus chemotherapy in the five RCTs included, but in this NMA, we found that there were differences in subgroup definitions.